Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine

Athaya Febriantyo Purnomo1,2, Fahrul Nurkolis3, Rony Abdi Syahputra4

  • 1Department of Oncology, University of Oxford, Oxford, OX3 7DQ, United Kingdom.

Heliyon
|July 23, 2024
PubMed

Insights

Balancing immunosuppression is key in kidney transplantation to fight cancer while ensuring graft survival. Personalized monitoring and targeted therapies offer hope for better outcomes.

Area of Science:

  • Onco-immunology
  • Transplantation Science
  • Immunology

Background:

  • The integration of onco-immunology and kidney transplantation presents a dual challenge: using immunosuppression to combat malignancies while preventing graft rejection.
  • Limited clinical data, genetic factors, economic issues, and narrow therapeutic windows complicate the management of post-transplant malignancies.

Purpose of the Study:

  • To elucidate the critical challenge of balancing immunosuppression for both malignancy control and graft survival in kidney transplant recipients.
  • To address the scarcity of clinical data on novel therapies and the impact of genetic variations on treatment responses.
  • To explore opportunities in precision medicine for improved patient outcomes.

Main Methods:

  • Review of current literature on onco-immunology and kidney transplantation.
  • Analysis of challenges including immunosuppression dichotomy, limited clinical data, and genetic influences.
  • Exploration of opportunities such as personalized immune monitoring and targeted therapies.

Main Results:

  • The dichotomy of immunosuppression poses a significant challenge, requiring careful balancing for onco-immunology and graft survival.
  • Personalized immune monitoring, targeted therapies, and minimized immunosuppression are promising avenues for improving patient quality of life.
  • Collaborative research and interdisciplinary cooperation are crucial for advancing the field.

Conclusions:

  • Enhanced graft survival and reduced post-transplant malignancy risks are achievable through strategic integration of onco-immunology and kidney transplantation.
  • Leveraging modern technology and patient-centric care can lead to more personalized and effective treatments.
  • The future of kidney transplantation holds promise for improved outcomes by addressing current challenges and embracing innovative approaches.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
883
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
352